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Development status of typhoid conjugate
vaccines globally
S. Sahastrabuddhe
International Vaccine Institute, Seoul, Korea,
Republic of
Abstract: Salmonella Typhi, the bacteria that causes Typhoid
fever, is one of the ﬁrst bacterium cultured and isolated. This
scourge still affects many children and adults mainly in the poor
communities in the developing countries. There are currently two
moderately efﬁcacious typhoid vaccines that are licensed in many
countries and one of themhas been prequaliﬁed byWHO, but there
are limitations to these vaccines in terms of storage conditions, age
of administration and need for revaccination because of limited
efﬁcacy. There are new vaccine candidates in the pipeline using
conjugation technology or recombinant DNA technology. Two of
these conjugate vaccines are available in India and although the
data is still unclear about their effectiveness, they should be uti-
lized to better control the disease. In this presentation, we will get
updates on the current status of vaccine development for various
typhoid conjugate vaccines and ways forward.
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Strategies on containing and treating drug
resistant typhoid in low and middle-income
contries
A. Arjyal
Oxford University Clinical Research Unit, Lalitpur,
Nepal
Abstract: Multiple strategies for the patient and clinician, and
for the population and policymakers should be urgently schemed
to counter drug resistant enteric fever in LMICs.
The usual patient-clinician interface, a single meeting at the
point of care, with one or two follow-ups afterwards, should be
extended both retrospectively and prospectively. Retrospectively,
with a careful screening and documentation of putative expo-
sures in the probable incubation period, and prospectively, with a
post-treatment tracing of close contacts for features of illness and
monitoring of the patient for relapse or treatment failure. Where
blood-culture is available, pairing of clinical data with suscepti-
bility data should be carried out. All this information should be
notiﬁed to an empowered local public health body so that pre-
ventive measures may be instituted promptly. Clinicians and other
team-members involvedmustbe rewarded forpreventionandcon-
trol efforts.
Promulgation of current diagnosis and treatment guidelines,
readily accessible and implementable with local resources, should
be carriedout routinely. This shouldbebasedona constant pipeline
of treatment studies, preferably randomised controlled trials, con-
ducted in an area with a similar susceptibility pattern. As an
example, the ﬂuoroquinolones, drugs of choice until quite recently,
shouldn’t beused inmostof SouthAsia,where there is awidespread
circulation of fully resistant strains, and agencies such as the WHO
should promptly endorse a fact as such.
Notiﬁcation and guideline access should exploit thewidespread
availability of web resources and mobile communications.
The development of rapid diagnostic tests must be prioritized
and the way must be paved for the discovery and production of
newer antimicrobials and rediscovery and reuse of older agents
hitherto no longer in use. Awareness about antibiotics should be
increased and stringent controls over antibiotic use should be exer-
cised. Vaccination, even if it bewith the existing Vi polysachharide,
despite its limited efﬁcacy or highmarket prices, can be carried out
selectively in populations, age groups or geographic areas at a high
risk of disease.
Theprovisionofhygiene, sanitationandsafedrinkingwatermay
need tremendous investments in infrastructure and can be very
difﬁcult to attain in a short span of time. Until such a time, given
the high costs of resistant disease to the individual and society, the
additional strategic steps to contain it outlined above are deﬁnitely
worth the extra endeavours.
http://dx.doi.org/10.1016/j.ijid.2016.02.189
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Global typhoid policy recommendations
A. Zaidi
Bill & Melinda Gates Foundation, Seattle, WA, USA
Abstract: The burden of typhoid is signiﬁcant and occurs largely
in children, with the highest rates occurring in children under
5 years of age living in poor urban environments in South Asia
and sub-Saharan Africa. Water scarcity, climate change, and rapid
uncontrolledurbanization in lowand low-middle incomecountries
may mitigate any improvements in water, sanitation and hygiene
infrastructure historically seen with socio-economic development,
and lead to conditions favoring more typhoid transmission in the
future. In addition, the alarming increases in antibiotic resistance
and theemergenceof agloballypervasiveanddominantmulti-drug
resistant strain (H58) seriously limits the oral therapeutic options
available and has the potential to drive increased burden and case
fatality.
Despite the substantial burden and the high probability that
effective typhoid conjugate vaccines (TCVs) will be available in
the near future, there has been a lack of global momentum for
achieving typhoid control. In order to align the global commu-
nity towards concerted action on typhoid, an aggressive goal for
global typhoid control, and an action plan is needed. We believe
aggressive typhoid control is achievable through an integrated
approach including improving surveillance systems to accurately
